Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | PMM2 | O15305 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902315 | 1.00 | ERN1 (0.48) | ERN1ENPP2ALDH1A1KDM4ELOX | |
| SCHEMBL29116321 | 0.91 | KMT2A (0.47) | ERN1ENPP2ALDH1A1KDM4ELOX | |
| SCHEMBL224885 | 0.83 | ENPP2 (0.46) | ERN1ENPP2ALDH1A1KDM4EMGLL | |
| SCHEMBL3763655 | 0.83 | HPGD (0.49) | ENPP2ALDH1A1KDM4EMGLLMEN1 | |
| SCHEMBL29957433 | 0.83 | ENPP2 (0.46) | ERN1ENPP2ALDH1A1KDM4EMGLL | |
| SCHEMBL7406706 | 0.82 | MEN1 (0.55) | ERN1ALDH1A1LOXMEN1KMT2A | |
| SCHEMBL29951715 | 0.81 | HPGD (0.63) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12538313 | 0.81 | GABRA1 (0.48) | ENPP2ALDH1A1KDM4EMGLLHPGD | |
| SCHEMBL1771787 | 0.81 | HPGD (0.63) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3784889 | 0.80 | ALDH1A1 (0.41) | ERN1ALDH1A1KMT2AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | UNIV MASARYKOVA (CZ) | 2025-11-20 | — | — | US | disclosed |
| WO-2005073205-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005067923-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-1537076-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-20040143006-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-22 | — | — | US | disclosed |
| WO-2004022533-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | ERN1 428/4885ENPP2 3499/4885ALDH1A1 2086/4885 |
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | FLT3, ROS1, MAP4K2 | ERN1 1994/4885ENPP2 1040/4885ALDH1A1 2094/4885 |
| US-20040143006-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | ERN1 2590/4885ENPP2 1044/4885ALDH1A1 722/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | ERN1 457/4885ENPP2 2016/4885ALDH1A1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.